ArticleJournal of functional biomaterials2022
Enhanced In Vitro Biocompatible Polycaprolactone/Nano-Hydroxyapatite Scaffolds with Near-Field Direct-Writing Melt Electrospinning Technology.
Article in Journal of functional biomaterials, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Bone-Mimetic Osteon Microtopographies on Poly-ε-Caprolactone Enhance the Osteogenic Potential of Human Mesenchymal Stem Cells.Macromolecular bioscience · 2025Article
- Recent advances in gradient biomimetic scaffolds for tendon-bone interface regeneration.Frontiers in bioengineering and biotechnology · 2025Review
- An Analysis of the Biocompatibility, Cytotoxicity, and Bone Conductivity of Polycaprolactone: An In Vivo Study.Polymers · 2024Article
- Cardiac tissue engineering: an emerging approach to the treatment of heart failure.Frontiers in bioengineering and biotechnology · 2024Review
- Assessment of 3D-Printed Polycaprolactone, Hydroxyapatite Nanoparticles and Diacrylate Poly(ethylene glycol) Scaffolds for Bone Regeneration.Pharmaceutics · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Polycaprolactone (PCL) scaffold is a common biological material for tissue engineering, owing to its good biocompatibility, biodegradability and plasticity. However, it is not suitable for osteoblast adhesion and regeneration of bone tissue due to its non-biological activity, poor mechanical strength, slow degradation speed, smooth surface and strong hydrophobicity. To improve the mechanical properties and biocompatibility of PCL scaffold, the PCL/nHA scaffolds were prepared by melting and blending different proportions of nano-hydroxyapatite (nHA) with PCL by the near-field direct-writing melt electrospinning technology in this study. The morphology, porosity, mechanical properties and in vitro biocompatibility of the PCL/nHA scaffolds were studied. The results showed that when the proportion of nHA was less than or equal to 25%, PCL/nHA composite scaffolds were easily formed in which bone marrow mesenchymal stem cells proliferated successfully. When the proportion of nHA was 15%, the PCL/nHA composite scaffolds had excellent structural regularity, good fiber uniformity, outstanding mechanical stability and superior biocompatibility. The PCL/nHA composite scaffolds were ideal scaffold materials, which would broaden their applications for bone tissue engineering.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.